BioIntervene
Signal active
Organization
Contact Information
Overview
BioIntervene is a preclinical-stage biopharmaceutical company committed to the discovery and development of effective and non-addictive medicines for chronic pain and other chronic inflammatory and neurodegenerative disorders. The Company was founded in 2014 based on insights from research at Saint Louis University and the National Institutes of Health (NIH). BioIntervene’s founding team has pioneered the understanding of adenosine A3 receptor biology, with a focus on developing first-in-class, selective adenosine A3 receptor agonists.
About
Industries
Biotechnology, Health Care, Pharmaceutical, Medical
Founded
2014
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
BioIntervene headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical sector. The company focuses on Biotechnology and has secured $1.9B in funding across 48 round(s). With a team of 1-10 employees, BioIntervene is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - BioIntervene, raised $5.6M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
0
Lead Investors
0
Total Funding Amount
$38.8M
Details
1
BioIntervene has raised a total of $38.8M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 30.0M |
Investors
BioIntervene is funded by 3 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Ed Hurwitz | - | FUNDING ROUND - Ed Hurwitz | 30.0M |
| BioIntervene | - | FUNDING ROUND - BioIntervene | 30.0M |
| MPM Capital | - | FUNDING ROUND - MPM Capital | 30.0M |
Recent Activity
There is no recent news or activity for this profile.